Organon Future Growth
Future criteria checks 2/6
Organon is forecast to grow earnings and revenue by 4.1% and 0.3% per annum respectively. EPS is expected to grow by 3.5% per annum. Return on equity is forecast to be 105.8% in 3 years.
Key information
4.1%
Earnings growth rate
3.5%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 0.3% |
| Future return on equity | 105.8% |
| Analyst coverage | Good |
| Last updated | 17 Jul 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6,553 | 1,071 | 1,115 | 1,170 | 6 |
| 12/31/2025 | 6,480 | 971 | 1,063 | 1,141 | 7 |
| 12/31/2024 | 6,414 | 751 | 870 | 1,221 | 7 |
| 3/31/2024 | 6,347 | 1,047 | 458 | 761 | N/A |
| 12/31/2023 | 6,263 | 1,023 | 538 | 799 | N/A |
| 9/30/2023 | 6,150 | 585 | 424 | 669 | N/A |
| 6/30/2023 | 6,168 | 754 | 320 | 725 | N/A |
| 3/31/2023 | 6,145 | 746 | 431 | 849 | N/A |
| 12/31/2022 | 6,174 | 917 | 431 | 858 | N/A |
| 9/30/2022 | 6,292 | 1,011 | 138 | 638 | N/A |
| 6/30/2022 | 6,355 | 1,107 | 343 | 689 | N/A |
| 3/31/2022 | 6,365 | 1,304 | 564 | 1,077 | N/A |
| 12/31/2021 | 6,304 | 1,351 | 1,970 | 2,458 | N/A |
| 9/30/2021 | 6,314 | 1,525 | 2,370 | 2,841 | N/A |
| 6/30/2021 | 6,327 | 1,762 | 2,304 | 2,761 | N/A |
| 3/31/2021 | 6,258 | 1,917 | 2,772 | 3,025 | N/A |
| 12/31/2020 | 6,532 | 2,256 | 1,932 | 2,187 | N/A |
| 12/31/2019 | 7,777 | 3,306 | 2,675 | 2,767 | N/A |
| 12/31/2018 | 9,777 | 2,153 | 3,586 | 3,687 | N/A |
| 12/31/2017 | 10,500 | 1,801 | N/A | 3,419 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7XP's forecast earnings growth (4.1% per year) is above the savings rate (0.7%).
Earnings vs Market: 7XP's earnings (4.1% per year) are forecast to grow slower than the German market (18.9% per year).
High Growth Earnings: 7XP's earnings are forecast to grow, but not significantly.
Revenue vs Market: 7XP's revenue (0.3% per year) is forecast to grow slower than the German market (5.2% per year).
High Growth Revenue: 7XP's revenue (0.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 7XP's Return on Equity is forecast to be very high in 3 years time (105.8%).